false 0001625101 0001625101 2026-03-17 2026-03-17

 

 

 

 

Date of Report (Date of Earliest Event Reported): March 17, 2026

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

On March 17, 2026, Pulse Biosciences, Inc. (the “Company”) issued a press release announcing an organizational realignment to support the Company’s increasing focus on developing its nsPFA electrophysiology catheters and other cardiac devices for the treatment of atrial fibrillation (“AFib”). This decision follows the Company’s release of unprecedented clinical data, on February 5, 2026, from its first in human feasibility study of its proprietary nPulse Cardiac Catheter System in patients with paroxysmal AFib. In the short-term, this announced realignment will result in a reduction in the number of employees in the Company’s sales and marketing functions, while it continues to actively recruit into its other product development functions.

 

A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

 

(d) Exhibits

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.